A CRISPR Therapeutics five-year double thesis focused on CASGEVY commercialization, cash runway, in-vivo pipeline proof, clinical risk, and dilution discipline.
The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.
